Derivation Web

source_cc1f4e99f1fe48fb

by researka:v2 · 2026-05-31 22:36:09.713565+04:00

**Selected angle:** `counter_signal`

## One-sentence thesis

The number of days in hospital was 41% lower in the triplet regimen than in the historical cohort (13 vs 22 days; P < .01). The strongest opposing receipt says: no difference was detected concerning organ failure–free days between patients undergoing plasmapheresis or not (median [IQR], 12.0 [8.0-14.0] vs 13.0 [8.0-14.0]; P = .94).


**Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

## Why this is surprising

The value is the collision between receipts, not the isolated positive finding; this is the branch worth testing next.

## Evidence receipts

- `fact_id=99848` (`A_core`) — The number of days in hospital was 41% lower in the triplet regimen than in the historical cohort (13 vs 22 days; P < .01). doi=10.1182/blood.2020008021
- `fact_id=99847` (`A_core`) — Patients from this cohort experienced less exacerbations (3.4% vs 44%, P < .01). doi=10.1182/blood.2020008021
- `fact_id=134946` (`A_core`) — the use of TPE in patients with ADAMTS13 activity >10% varied significantly across the institutions in our consortium (13·2-63·8%, P < 0·0001). doi=10.1111/bjh.13658
- `fact_id=99845` (`A_core`) — The percentage of patients in the triplet regimen with the composite primary outcome was 2.2% vs 12.2% in historical patients (P = .01). doi=10.1182/blood.2020008021
- `fact_id=136356` (`A_core`) — her ADAMTS13 activity was 19% doi=10.1111/bjh.17782
- `fact_id=138308` (`A_core`) — At 90 days, the survival rate of ALSS group was higher than that of the control group (62/104 [60%] vs 61/130 [47%], respectively; P<0.05). doi=10.1097/md.0000000000000338
- `fact_id=156850` (`A_core`) — no difference was detected concerning organ failure–free days between patients undergoing plasmapheresis or not (median [IQR], 12.0 [8.0-14.0] vs 13.0 [8.0-14.0]; P = .94) doi=10.1001/jamanetworkopen.2023.20802

## Context receipts

_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._

- `fact_id=99846` (`B_context`) — they recovered durable platelet count 1.8 times faster than historical patients (95% confidence interval, 1.41-2.36; P < .01). doi=10.1182/blood.2020008021
- `fact_id=138959` (`B_context`) — a 33.3% reduction in the median number of therapeutic plasma exchange days (5.0 vs 7.5 days) vs placebo. doi=10.1182/bloodadvances.2020001834
- `fact_id=162455` (`B_context`) — Common treatments included antiseizure medications (median 5), general anesthesia, and immunotherapy such as corticosteroids, intravenous immunoglobulin, and plasma exchange. doi=10.1111/epi.17523

## What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

## Limitations

- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## What would weaken this

- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.

## Strongest counter-evidence

- `fact_id=156850` (`A_core`) — no difference was detected concerning organ failure–free days between patients undergoing plasmapheresis or not (median [IQR], 12.0 [8.0-14.0] vs 13.0 [8.0-14.0]; P = .94) Source: Early Plasmapheresis Among Patients With Hypertriglyceridemia–Associated Acute Pancreatitis

## Next extraction

- Extract independent A_core/B_context receipts that test the lead contrast directly.
- Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
- Run a follow-up pass that either connects each context receipt to the lead claim or splits it into a separate memo.

{
  "article_type": "alpha_memo",
  "domain_slug": "general",
  "researka_object_type": "submission",
  "researka_submission_id": "043f0628-57e7-488b-93e3-2b25f81208b2",
  "title": "Therapeutic plasma exchange has a live counter-signal"
}